女性非ST段抬高型急性冠脉综合征管理的证据基础
本文综述女性非ST段抬高型急性冠脉综合征(NSTE-ACS)管理的证据基础。全球女性心血管病患病率2010年后略有上升,年轻女性急性心梗住院比例增加;女性接受指南推荐药物和血运重建治疗的比例低于男性,临床试验代表性不足(2010-2017年女性参与率<39%),现有指南风险分层策略可能不适用于女性,需专门招募女性的临床试验。
要点
- 女性急性心梗患者接受指南推荐药物和血运重建治疗的比例低于男性。
- 女性在心血管临床试验中代表性不足,2010-2017年参与率<39%。
- 现有ACS指南风险分层策略可能不适用于女性,需专门研究。
核心结论
- 女性ACS管理证据基础存在显著局限,亟需专门招募女性的精心设计临床试验。
研究设计与样本
- 综述,基于全球疾病负担研究及文献证据汇总。
主要发现
- 年轻女性急性心梗住院比例从1995-1999年27%升至2010-2014年32%。
- 女性急性心梗患者接受阿司匹林93.4% vs 94.7%、P2Y12抑制剂79.3% vs 86.1%、他汀73.7% vs 77.5%的比例低于男性。
- 女性接受血管造影aOR 0.71、经皮冠状动脉介入aOR 0.73,低于男性。
临床怎么用
- 临床应关注女性ACS患者接受指南推荐药物和血运重建治疗的不足。
- 现有指南风险分层策略用于女性时需谨慎,因缺乏当代治疗策略下女性专门研究。
局限性
- 证据基础存在显著局限,缺乏专门评估女性的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
According to the Global Burden of Disease study, in 2019, there were an estimated 275.2 million cases of cardiovascular disease (CVD) in women worldwide. Although there was a decrease in the global age-standardised prevalence of CVD in women between 1990 and 2010 (-5.8%), there has been a slight increase (1.0%) since 2010. There were an estimated 6.10 million deaths from CVD in women in 1990, rising to 8.94 million in 2019. Hospital admissions of young women with acute myocardial infarction (AMI) steadily increased from 27% in 1995-1999 to 32% in 2010-2014. Women with AMI compared with men are less likely to receive guideline-indicated pharmacological (aspirin 93.4% vs 94.7%, P2Y12 inhibitors 79.3% vs 86.1% and statins 73.7% vs 77.5%) and revascularisation treatments (angiography (adjusted OR (aOR) 0.71), percutaneous coronary intervention (aOR 0.73)). Women represent <39% of clinical cardiovascular trial participants between 2010 and 2017. Major factors of under-representation in studies included concerns about the burden of participation on health and time. Women were more likely than men to document caring responsibilities as reasons for not participating in a clinical trial. Current clinical practice guidelines recommending risk stratification to guide the appropriateness of an invasive strategy in the context of acute coronary syndrome (ACS) may not be applicable to women given lack of studies specifically evaluating women using contemporary treatment strategies. In our review, we identify significant limitations in the evidence base for the best care of women with ACS, emphasising the need for well-designed clinical trials specifically recruiting women.
引用
- Jackson, Alkhalil, Ratcovich, et al. Evidence base for the management of women with non-ST elevation acute coronary syndrome. Heart. 2022. PMID: 35064048. doi:10.1136/heartjnl-2021-320533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。